- Conditions
- HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985, Vic-trastuzumab Duocarmazine, Metastatic Cancer, Metastatic Breast Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic, HER2 Low Breast Cancer, GastroEsophageal Cancer, Gastroesophageal Adenocarcinoma, Endometrium Tumor, Ovarian Cancer, Ovarian Carcinoma, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2 Low HR Positive, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Bladder Cancer
- Interventions
- Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–71
of 71
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer
- Interventions
- entinostat
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland
- Conditions
- Cancer
- Interventions
- Fentanyl sublingual spray, Placebo
- Drug
- Lead sponsor
- INSYS Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Chandler, Arizona
- Conditions
- Endometrial Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
- Interventions
- Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 2,824 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Endometrial Cancer
- Interventions
- Paclitaxel, Pelvic Radiation, Dexamethasone, Cimetidine, Diphenhydramine
- Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2013
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Houston, Texas
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
- Interventions
- Paclitaxel, Cisplatin, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cancer
- Interventions
- aminocamptothecin colloidal dispersion
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
- Interventions
- Bevacizumab, Carboplatin, Cisplatin, Intensity-Modulated Radiation Therapy, Paclitaxel
- Biological · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 38
- States / cities
- Berkeley, California • Walnut Creek, California • Colorado Springs, Colorado + 31 more
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7
- Interventions
- Carboplatin, Cisplatin, Internal Radiation Therapy, Paclitaxel, Quality-of-Life Assessment, Radiation Therapy
- Drug · Radiation · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 813 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2024
- U.S. locations
- 655
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 407 more
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
- Interventions
- Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 952 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Fatigue, Neurotoxicity Syndrome, Obesity, Stage I Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Intensity-Modulated Radiation Therapy, Internal Radiation Therapy, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
- Radiation · Drug · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 533
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 352 more
- Conditions
- Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Adenocarcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Triple Negative Breast Cancer, Endometrial Carcinoma, Soft Tissue Sarcoma
- Interventions
- MM-310
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • San Francisco, California • Rochester, Minnesota + 2 more
- Conditions
- Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma, Epithelial Ovarian Carcinoma, Mesothelioma, Gastroenteropancreatic Neuroendocrine Tumor, SCLC, Gastric Carcinoma, Pancreatic Adenocarcinoma, Colorectal Carcinoma, Neuroendocrine Tumors
- Interventions
- Lurbinectedin, Irinotecan
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 4
- States / cities
- Santa Monica, California • Boston, Massachusetts • Houston, Texas
- Conditions
- Advanced Solid Cancers
- Interventions
- BNT329, CA19-9-targeting monoclonal antibody
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Orlando, Florida • Detroit, Michigan + 1 more
- Conditions
- Cancer, Solid Tumor
- Interventions
- CALAA-01
- Drug
- Lead sponsor
- Calando Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- Duarte, California • Los Angeles, California • San Antonio, Texas
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
- Interventions
- MT-4561
- Drug
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more
- Conditions
- Cancer
- Interventions
- PV701
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Endometrial Cancer
- Interventions
- medroxyprogesterone, tamoxifen citrate, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2009
- U.S. locations
- 122
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 84 more
- Conditions
- Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
- Interventions
- Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, High-Dose-Rate Vaginal Cuff Brachytherapy, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Multigated Acquisition Scan, Paclitaxel, Survey Administration, Trastuzumab/Hyaluronidase-oysk
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 409
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 307 more
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Neurotoxicity, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Sarcoma
- Interventions
- amifostine trihydrate, cisplatin, paclitaxel
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 8
- States / cities
- Orange, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
- Conditions
- Solid Tumor, Adult
- Interventions
- FT538, Cyclophosphamide, Fludarabine, Monoclonal antibody - Dose Escalation, Monoclonal antibody - Dose Expansion
- Drug · Combination Product
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more
- Conditions
- Ovarian, Melanoma, Renal, Prostate, Colorectal, Endometrial Carcinoma, Cervical Carcinoma, Testicular Cancer, Thyroid Cancer, Small Cell Lung Carcinoma, Mesothelioma, Breast Carcinoma, Esophageal Carcinoma, Gastric Cancer, Pancreatic Carcinoma, Neuroendocrine Cancer, Liver Cancer, Gallbladder Cancer, Biliary Tract Cancer, Anal Carcinoma, Bone Sarcomas, Soft Tissue Sarcomas, Carcinoma of Unknown Origin, Primary
- Interventions
- PSMA/PRAME
- Biological
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 5
- States / cities
- Tuscon, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 2 more
- Conditions
- Endometrial Cancer
- Interventions
- Vaginal Brachytherapy, Cisplatin, Whole Abdominal Radiation [WAR] Therapy
- Radiation · Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Miami, Florida